MARKERS FOR EARLY DIAGNOSIS OF OVARIAN CANCER, MONITORING DURING THERAPY, AND NEW THERAPY OPTIONS DURING AND AFTER CHEMOTHERAPY
申请人:The Board of Trustees of the University of Arkansas
公开号:US20140193426A1
公开(公告)日:2014-07-10
The inventors have identified several proteases and a protease inhibitor that are overexpressed in ovarian cancer tumors. They have developed monoclonal antibodies against the proteins and shown that they can be detected in serum and the levels of the proteins in serum fluctuate during cancer treatment. They have shown that serum assays for the proteases and protease inhibitor can be used for early detection of ovarian cancer, and for monitoring cancer treatment.